Dianthus Therapeutics, Inc. /DE/ Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Dianthus Therapeutics, Inc. /DE/ (DNTH) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $44.31 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-08-04
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $39.81, a 134.31% increase year-over-year.
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-03-31 was $16.99, a 21.10% increase year-over-year.
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-03-31 was $14.03.
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $18.27, a 13.06% increase from fiscal 2024.
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $16.16, a 56.89% increase from fiscal 2023.
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $10.30.
- Dianthus Therapeutics, Inc. /DE/ share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2020 was $6.90, a 14.05% increase from fiscal 2019.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $44.31 10-Q · filed 2026-08-04 | ||||
| 2026-03-31 | $39.81 10-Q · filed 2026-05-05 | ||||
| 2025-12-31 | $18.27 10-K · filed 2026-03-09 | ||||
| 2025-09-30 | $18.02 10-Q · filed 2025-11-05 | ||||
| 2025-06-30 | $16.27 10-Q · filed 2025-08-07 | ||||
| 2025-03-31 | $16.99 10-Q · filed 2025-05-12 | ||||
| 2024-12-31 | $16.16 10-K · filed 2025-03-11 | ||||
| 2024-09-30 | $15.91 10-Q · filed 2024-11-07 | ||||
| 2024-06-30 | $15.72 10-Q · filed 2024-08-08 | ||||
| 2024-03-31 | $14.03 10-Q · filed 2024-05-09 | ||||
| 2023-12-31 | $10.30 10-K · filed 2024-03-21 | ||||
| 2023-09-30 | $10.86 10-Q · filed 2023-11-09 | ||||
| 2022-12-31 | $6.24 8-K · filed 2023-12-21 | $1.48 10-K · filed 2023-03-23 | |||
| 2021-12-31 | $4.31 8-K · filed 2023-12-21 | $6.32 10-K · filed 2022-03-08 | |||
| 2020-12-31 | $6.90 10-K · filed 2022-03-08 | ||||
| 2019-12-31 | $6.05 10-K · filed 2021-03-03 | ||||
| 2018-12-31 | $6.56 10-K · filed 2020-03-03 | ||||
| 2017-12-31 | $3.31 10-K · filed 2020-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |